Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1279

1.

Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.

Botkin JR, Smith KR, Croyle RT, Baty BJ, Wylie JE, Dutson D, Chan A, Hamann HA, Lerman C, McDonald J, Venne V, Ward JH, Lyon E.

Am J Med Genet A. 2003 Apr 30;118A(3):201-9.

PMID:
12673648
2.

Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.

Lerman C, Hughes C, Croyle RT, Main D, Durham C, Snyder C, Bonney A, Lynch JF, Narod SA, Lynch HT.

Prev Med. 2000 Jul;31(1):75-80.

PMID:
10896846
3.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

4.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.

PMID:
19347608
5.

Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing.

Peshkin BN, Schwartz MD, Isaacs C, Hughes C, Main D, Lerman C.

Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1115-8.

6.
7.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
8.

Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL.

J Natl Cancer Inst. 1999 Sep 1;91(17):1475-9.

9.

Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.

J Clin Oncol. 2003 May 1;21(9):1675-81.

PMID:
12721241
10.

Psychological impact of receiving a BRCA1/BRCA2 test result.

Lodder L, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, van der Meer CA, van den Ouweland AM, Niermeijer MF.

Am J Med Genet. 2001 Jan 1;98(1):15-24.

PMID:
11426450
11.

Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.

van Roosmalen MS, Verhoef LC, Stalmeier PF, Hoogerbrugge N, van Daal WA.

J Clin Oncol. 2002 Apr 15;20(8):2092-100.

PMID:
11956270
12.

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR.

Ann Intern Med. 2006 Mar 21;144(6):397-406.

PMID:
16549852
13.

Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.

Vasen HF, Haites NE, Evans DG, Steel CM, Møller P, Hodgson S, Eccles D, Morrison P, Stoppa Lyonet D, Chang-Claude J, Caligo M.

Eur J Cancer. 1998 Nov;34(12):1922-6.

PMID:
10023316
14.

Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred.

Kinney AY, Simonsen SE, Baty BJ, Mandal D, Neuhausen SL, Seggar K, Holubkov R, Bloor L, Smith K.

J Genet Couns. 2006 Aug;15(4):293-305.

PMID:
16865561
15.

Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K.

J Clin Oncol. 2002 Mar 1;20(5):1260-8.

PMID:
11870168
16.

Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

Phillips KA, Jenkins MA, Lindeman GJ, McLachlan SA, McKinley JM, Weideman PC, Hopper JL, Friedlander ML; kConFab Investigators.

Clin Genet. 2006 Sep;70(3):198-206.

PMID:
16922722
17.

Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.

Lodder L, Frets PG, Trijsburg RW, Tibben A, Meijers-Heijboer EJ, Duivenvoorden HJ, Wagner A, van Der Meer CA, Devilee P, Cornelisse CJ, Niermeijer MF.

Eur J Hum Genet. 2001 Jul;9(7):492-500.

18.

Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer.

Claes E, Evers-Kiebooms G, Decruyenaere M, Denayer L, Boogaerts A, Philippe K, Legius E.

Behav Med. 2005 Fall;31(3):93-105.

PMID:
16252621
19.

Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.

Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P.

J Natl Cancer Inst. 2003 Jul 16;95(14):1072-8.

20.

Screening adherence in BRCA1/2 families is associated with primary physicians' behavior.

Tinley ST, Houfek J, Watson P, Wenzel L, Clark MB, Coughlin S, Lynch HT.

Am J Med Genet A. 2004 Feb 15;125A(1):5-11.

PMID:
14755459
Items per page

Supplemental Content

Write to the Help Desk